Glucotrack Publishes Peer-Reviewed Study Validating Long-Term Accuracy of Continuous Blood Glucose Monitor
GCTK sits 34% above its 52-week low of $0.619.
Summary
Glucotrack announced the publication of a peer-reviewed study validating the long-term accuracy and stability of its continuous blood glucose monitoring (CBGM) technology, a key milestone for its FDA submission pathway.
Key Events · Product Development and Regulatory · GCTK
-
Peer-Reviewed Study Published
Glucotrack announced the publication of a scientific article in The Journal of Diabetes Research, providing external validation for its continuous blood glucose monitoring (CBGM) technology.
-
Strong Preclinical Results
An in-vivo ovine study demonstrated a weighted average Mean Absolute Relative Difference (MARD) of 6.8% over periods of up to 240 days, indicating excellent accuracy and consistent performance, with no device-related adverse safety events.
-
Supports FDA Submission
The positive long-term accuracy and stability data reinforce the company's confidence in the CBGM platform's design and are crucial for advancing towards an Investigational Device Exemption (IDE) submission with the FDA.
Analysis · GCTK · Industrial Applications And Services
Glucotrack, a medical technology company, announced the publication of a peer-reviewed study demonstrating the long-term accuracy and stability of its continuous blood glucose monitoring (CBGM) technology. The in-vivo ovine study showed a strong Mean Absolute Relative Difference (MARD) of 6.8% over 240 days with no adverse events. This external validation is a critical step for the company, reinforcing confidence in its platform's design and supporting its progression towards an Investigational Device Exemption (IDE) submission with the FDA. For a micro-cap company like Glucotrack, positive preclinical data is highly significant, as it de-risks the core technology and strengthens the path to commercialization.
How filings like this one have moved
In the 30 days to Oct 9, 2026, 36.7% of the 1061 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.62%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GCTK was trading at $0.83 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.6M. The 52-week trading range was $0.62 to $15.90. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.